Two rulings by the Supreme Court earlier this week provide some positive news for the drug discovery business. The first ruling minimizes patient litigation against makers of generic drugs. Generic drug makers use the same warning label as the initial company that discovered the drug. The court basically says it trusts the FDA’s judgement on warning labels – and generic drug companies can not be suited under state law. The second ruling allows more targeted marketing from pharmaceutical companies to doctors based on their prescription records.
Here is a nice article by 2009 Pulitzer Prize Finalist Adam Liptak in the NY Times summarizing the court’s debate.
For an analysis of the implications for the original organization that discovered the drug vs generic manufactures, see “Generic Drug Warning Labels: The Supreme Court Speaks” from Derek Lowe’s widely read In The Pipeline blog.
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!
CDD Vault: Drug Discovery Informatics your whole project team will embrace!
Tag(s):
CDD Blog
Other posts you might be interested in
View All Posts
Events
14 min
March 27, 2025
Collaborative Drug Discovery's Inaugural Canadian User Group Meeting
Read More
CDD Blog
5 min
March 21, 2025
Drug Discovery Informatics for Big Pharma: Key Webinar Insights
Read More
CDD Vault Updates
3 min
March 19, 2025
CDD Vault Update (March #2 2025): Macromolecule Atomistic Rendering, AI Datasets, Import Inventory Locations, Larger Inventory Boxes, Dark Mode
Read More